IDM-2101
Phase 2- Indications
- Non-small cell lung cancer
Company intelligence / Profile preview
IDM Pharma developed innovative immunotherapies for cancer, aiming to activate the immune system against tumors. The company had several programs in clinical development and completed asset sales related to infectious disease programs before being acquired. It was known for leveraging adaptive immune responses and therapeutic vaccines[1][3][5]. No recent clinical results are available as the company has been acquired and no longer operates independently.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on IDM Pharma.